Objective Every year around 350.000 patients in the EU are newly diagnosed with colorectal cancer (CRC). Although € 1.4 Billion are spent on CRC drugs, the majority of patients fail to respond to therapy because their individual tumor is resistant to the chosen treatment. These patients suffer from unwanted side effects and after two month are switched to another drug regime – giving rise to additional drug and hospital costs. 2cureX ApS, a Danish SME, has developed IndiTreat, an ex-vivo chemosensitivity test. The functional profiling test uses 3D-cellular “micro-tumors” prepared directly from a patient’s tumor. It allows the selection of the most effective and least toxic drug regimen for each individual patient prior to initiating treatment. For the oncologists and patients this greatly improves the probability of selecting an effective drug treatment. The main objective of MicroCaT is to clinically validate the benefits of IndiTreat in an interventional multi-national study with metastatic (stage IV) colorectal cancer patients. Demonstrating the clinical utility and cost effectiveness of IndiTreat will pave the way for uptake in EU clinical guidelines and reimbursement arrangements. Communication and dissemination of MicroCaT project activities will be key to raise the consciousness of this breakthrough innovation with clinicians, patients and health assessment authorities. Commercializing IndiTreat for CRC patients will enable 2cureX to significantly grow and expand its business. With the potential to predict therapy responses in all solid forms of cancer, the use of IndiTreat will eventually result in multi-millions of health care costs savings as well as improving the quality of life of cancer patients across Europe. Fields of science medical and health sciencesbasic medicineimmunologymedical and health sciencesclinical medicineoncologycolorectal cancermedical and health sciencesclinical medicineoncologypancreatic cancer Programme(s) H2020-EU.3.1. - SOCIETAL CHALLENGES - Health, demographic change and well-being Main Programme H2020-EU.3.1.3. - Treating and managing disease Topic(s) SMEInst-05-2016-2017 - Supporting innovative SMEs in the healthcare biotechnology sector Call for proposal H2020-SMEInst-2016-2017 See other projects for this call Sub call H2020-SMEINST-2-2016-2017 Funding Scheme SME-2 - SME instrument phase 2 Coordinator 2CUREX A/S Net EU contribution € 2 623 526,11 Address FRUEBJERGVEJ 3 2100 Kobenhavn Denmark See on map SME The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed. Yes Region Danmark Hovedstaden Byen København Activity type Private for-profit entities (excluding Higher or Secondary Education Establishments) Links Contact the organisation Opens in new window Website Opens in new window Participation in EU R&I programmes Opens in new window HORIZON collaboration network Opens in new window Total cost € 2 986 699,25 Participants (1) Sort alphabetically Sort by Net EU contribution Expand all Collapse all Third-party Legal entity other than a subcontractor which is affiliated or legally linked to a participant. The entity carries out work under the conditions laid down in the Grant Agreement, supplies goods or provides services for the action, but did not sign the Grant Agreement. A third party abides by the rules applicable to its related participant under the Grant Agreement with regard to eligibility of costs and control of expenditure. 2CUREX GMBH Germany Net EU contribution € 363 173,14 Address FALKENRIED 88 20251 HAMBURG See on map SME The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed. Yes Region Hamburg Hamburg Hamburg Activity type Private for-profit entities (excluding Higher or Secondary Education Establishments) Links Contact the organisation Opens in new window Participation in EU R&I programmes Opens in new window HORIZON collaboration network Opens in new window Total cost € 363 173,14